# Bevacizumab in Treating Patients With Angiosarcoma

> **NCT00288015** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 32 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT00288015
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2013-06-06
- **Final completion:** 2016-11-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288015, "Bevacizumab in Treating Patients With Angiosarcoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00288015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*